Literature DB >> 20421138

The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates.

Elizabeth Fox1, Nalini Jayaprakash, Tuyet-Hang Pham, Ayana Rowley, Cynthia L McCully, Frank Pucino, Raphaela Goldbach-Mansky.   

Abstract

Anakinra improves the central nervous system manifestations of neonatal-onset multisystem inflammatory disease, which is mediated by IL-1beta oversecretion. The cerebrospinal fluid (CSF) penetration of the IL-1 receptor antagonist anakinra was studied in rhesus monkeys after intravenous doses of 3 and 10 mg/kg. Drug exposure (area under concentration-time curve) in CSF was 0.28% of that in serum. The average CSF concentration at 3 mg/kg was 1.8 ng/mL, which is 30-fold higher than endogenous CSF levels of IL-1Ra. The CSF penetration was not dose-dependent, indicating that the CSF penetration was not saturated in the 3 to 10 mg/kg dose range. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20421138      PMCID: PMC2887614          DOI: 10.1016/j.jneuroim.2010.03.022

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

Review 1.  Passage of cytokines across the blood-brain barrier.

Authors:  W A Banks; A J Kastin; R D Broadwell
Journal:  Neuroimmunomodulation       Date:  1995 Jul-Aug       Impact factor: 2.492

2.  A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid.

Authors:  C L McCully; F M Balis; J Bacher; J Phillips; D G Poplack
Journal:  Lab Anim Sci       Date:  1990-09

3.  Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey.

Authors:  Elizabeth Fox; Peter M Bungay; John Bacher; Cynthia L McCully; Robert L Dedrick; Frank M Balis
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

4.  Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.

Authors:  Shana S Jacobs; Elizabeth Fox; Christopher Dennie; Lindsey B Morgan; Cynthia L McCully; Frank M Balis
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

Review 5.  Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation.

Authors:  Charles A Dinarello
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

6.  Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism.

Authors:  W A Banks; L Ortiz; S R Plotkin; A J Kastin
Journal:  J Pharmacol Exp Ther       Date:  1991-12       Impact factor: 4.030

7.  Cerebral subarachnoid sampling of cerebrospinal fluid in the rhesus monkey.

Authors:  J D Bacher; F M Balis; C L McCully; K S Godwin
Journal:  Lab Anim Sci       Date:  1994-04

8.  Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans.

Authors:  E V Granowitz; R Porat; J W Mier; J P Pribble; D M Stiles; D C Bloedow; M A Catalano; S M Wolff; C A Dinarello
Journal:  Cytokine       Date:  1992-09       Impact factor: 3.861

9.  Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier.

Authors:  E G Gutierrez; W A Banks; A J Kastin
Journal:  J Neuroimmunol       Date:  1994-12       Impact factor: 3.478

10.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

Authors:  Raphaela Goldbach-Mansky; Natalie J Dailey; Scott W Canna; Ana Gelabert; Janet Jones; Benjamin I Rubin; H Jeffrey Kim; Carmen Brewer; Christopher Zalewski; Edythe Wiggs; Suvimol Hill; Maria L Turner; Barbara I Karp; Ivona Aksentijevich; Frank Pucino; Scott R Penzak; Margje H Haverkamp; Leonard Stein; Barbara S Adams; Terry L Moore; Robert C Fuhlbrigge; Bracha Shaham; James N Jarvis; Kathleen O'Neil; Richard K Vehe; Laurie O Beitz; Gregory Gardner; William P Hannan; Robert W Warren; William Horn; Joe L Cole; Scott M Paul; Philip N Hawkins; Tuyet Hang Pham; Christopher Snyder; Robert A Wesley; Steven C Hoffmann; Steven M Holland; John A Butman; Daniel L Kastner
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

View more
  19 in total

1.  Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes.

Authors:  Cailin H Sibley; Nikki Plass; Joseph Snow; Edythe A Wiggs; Carmen C Brewer; Kelly A King; Christopher Zalewski; H Jeffrey Kim; Rachel Bishop; Suvimol Hill; Scott M Paul; Patrick Kicker; Zachary Phillips; Joseph G Dolan; Brigitte Widemann; Nalini Jayaprakash; Frank Pucino; Deborah L Stone; Dawn Chapelle; Christopher Snyder; John A Butman; Robert Wesley; Raphaela Goldbach-Mansky
Journal:  Arthritis Rheum       Date:  2012-07

2.  Blocking IL-1beta to slow down progression of ALS?

Authors:  Jos W M van der Meer; Anna Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

Review 3.  Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions.

Authors:  Michelle A Erickson; William A Banks
Journal:  Pharmacol Rev       Date:  2018-04       Impact factor: 25.468

Review 4.  Targeting the NLRP3 inflammasome in inflammatory diseases.

Authors:  Matthew S J Mangan; Edward J Olhava; William R Roush; H Martin Seidel; Gary D Glick; Eicke Latz
Journal:  Nat Rev Drug Discov       Date:  2018-07-20       Impact factor: 84.694

5.  Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation.

Authors:  Jackeline Rodriguez-Smith; Yen-Chih Lin; Wanxia Li Tsai; Hanna Kim; Gina Montealegre-Sanchez; Dawn Chapelle; Yan Huang; Cailin H Sibley; Massimo Gadina; Robert Wesley; Bibiana Bielekova; Raphaela Goldbach-Mansky
Journal:  Arthritis Rheumatol       Date:  2017-05-10       Impact factor: 10.995

6.  Role of the IL-1 receptor antagonist in ethanol-induced regulation of GABAergic transmission in the central amygdala.

Authors:  M Bajo; M A Herman; F P Varodayan; C S Oleata; S G Madamba; R A Harris; Y A Blednov; M Roberto
Journal:  Brain Behav Immun       Date:  2014-12-03       Impact factor: 7.217

7.  The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.

Authors:  Micol Romano; Z Serap Arici; David Piskin; Sara Alehashemi; Daniel Aletaha; Karyl Barron; Susanne Benseler; Roberta A Berard; Lori Broderick; Fatma Dedeoglu; Michelle Diebold; Karen Durrant; Polly Ferguson; Dirk Foell; Jonathan S Hausmann; Olcay Y Jones; Daniel Kastner; Helen J Lachmann; Ronald M Laxer; Dorelia Rivera; Nicola Ruperto; Anna Simon; Marinka Twilt; Joost Frenkel; Hal M Hoffman; Adriana A de Jesus; Jasmin B Kuemmerle-Deschner; Seza Ozen; Marco Gattorno; Raphaela Goldbach-Mansky; Erkan Demirkaya
Journal:  Arthritis Rheumatol       Date:  2022-05-27       Impact factor: 15.483

8.  Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS).

Authors:  M H Haverkamp; E van de Vosse; R Goldbach-Mansky; S M Holland
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

9.  Lipopolysaccharide-Induced Chorioamnionitis Promotes IL-1-Dependent Inflammatory FOXP3+ CD4+ T Cells in the Fetal Rhesus Macaque.

Authors:  Cesar M Rueda; Pietro Presicce; Courtney M Jackson; Lisa A Miller; Suhas G Kallapur; Alan H Jobe; Claire A Chougnet
Journal:  J Immunol       Date:  2016-04-01       Impact factor: 5.422

10.  The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.

Authors:  Roberta Caorsi; Loredana Lepore; Francesco Zulian; Maria Alessio; Achille Stabile; Antonella Insalaco; Martina Finetti; Antonella Battagliese; Giorgia Martini; Chiara Bibalo; Alberto Martini; Marco Gattorno
Journal:  Arthritis Res Ther       Date:  2013-02-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.